New cocktail of drugs shows promise in battling tough colorectal cancer
NCT ID NCT05959356
First seen Jan 07, 2026 · Last updated Jun 23, 2026 · Updated 25 times
Summary
This phase II trial is testing whether a new combination of drugs (cetuximab, envafolimab, and a stronger chemo mix) works better than the current standard treatment for people with a specific type of advanced colorectal cancer that has spread. The study will enroll 198 participants and compare how long the cancer stays under control. The goal is to see if the new combo can shrink tumors more effectively and potentially allow more patients to have surgery to remove remaining cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC COLORECTAL CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Affiliated Cancer Hospital of Guizhou Medical University
RECRUITINGGuiyang, Guizhou, 550000, China
Contact Phone: •••-•••-••••
-
The First People's Hospital of Foshan
RECRUITINGFoshan, Guangdong, 528000, China
Contact Phone: •••-•••-••••
-
The Sixth Affiliated Hospital of Sun Yat-sen University
RECRUITINGGuangzhou, Guangdong, 510655, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Cetuximab, envafolimab, and a chemotherapy cocktail (mFOLFOXIRI)
What this could lead to
If successful, this could offer a more effective first-line treatment option for people with a specific type of advanced colorectal cancer, potentially shrinking tumors more and delaying disease progression.
What could go wrong
This is an early phase II trial with only 198 participants, so results are not definitive. The new combination may cause more severe side effects than the standard treatment, and it may not prove to be more effective in the long run.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.